NeurAxis(NRXS)

Focus: NeurAxis is a public biotechnology company focused on stimulative pain relief devices based in Carmel, Indiana. The company operates as a medical device innovator in the neuromodulation space.

Profile data last refreshed 54m ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About NeurAxis

AI assessmentNot Hiring

No open roles listed right now. Follow NeurAxis to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$3M

FY2025

Key Products

Stimulative Pain Relief Device

Chronic pain management

Growth

Flagship product generating early commercial revenue but market penetration data unavailable.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Help build intelligence for NeurAxis

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status provides equity upside and career stability relative to pre-revenue startups
Focused specialty in pain relief devices offers deep domain expertise and narrow competitive moat
Early revenue generation ($3M FY2025) signals market validation and traction toward profitability

Watch Out For

Severe cash constraints ($4M on hand) with $8.2M net loss in FY2025 raise sustainability concerns
Zero active clinical trials and no pipeline programs visible suggest limited near-term growth catalysts
No current job openings (0 active roles) indicates hiring freeze and potential restructuring risk

Generated by Claude from NeurAxis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Interview Prep Quick Facts

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Financials (FY2025)

Revenue

$3M9%

R&D Spend

$434K(16%)156%

Net Income

-$8M

Cash

$4M

Source: SEC 10-K Filing